24 results for «107»
24 results
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/whats-new-on-pcronline/2025/esc/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Summary and take home messages of the late-breaking clinical trials presented during #TCTConnect 2020
19 Oct 2020
Vijay Kunadian provides a summary of the coronary & structural late-breaking studies presented during TCT Connect 2020 and shares some take-home messages. See how these studies might influence your daily practice!

Author

- ← previous
- 1
- 2
- next →